Autopsy report · NCT02732938

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

“Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

PF-04136309; Nab-paclitaxel; Gemcitabine

Participants

22

Sites

18

Countries

United States

Trials that died the same way

• Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
  “A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.” (72% match in meaning)
• A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
  “Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities.” (67% match in meaning)
• A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
  “It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.” (65% match in meaning)
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
  “termination due to portfolio prioritization” (64% match in meaning)
• Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
  “The study has been terminated due to a change in internal prioritization and not due to any safety concerns.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.